ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vansteenkiste, J.
Right arrow Articles by Demedts, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vansteenkiste, J.
Right arrow Articles by Demedts, M.
Eur Respir J 1996; 9: 1707-1712
Copyright © ERS Journals Ltd 1996

Original Articles

Hormonal treatment in advanced non-small cell lung cancer: fact or fiction?

JF Vansteenkiste, JP Simons, EF Wouters, and MG Demedts

In patients with advanced non-small cell lung cancer, cachexia is an important cause of morbidity and mortality. The pathogenic mechanism of this finding, usually referred to as "cancer anorexia and cachexia syndrome" (CACS), is complex and far from completely understood, but a disturbed equilibrium between possible food intake and metabolic needs seems to be fundamental. The literature data on the treatment options in advanced non-small cell lung cancer (NSCLC) with cachexia are reviewed. Based on the clinical studies on cancer cachexia, some recommendations for the therapeutic approach of this disorder in patients with advanced NSCLC can be given. Metoclopramide is easily administered, can alleviate gastric disturbances, but probably does not correct the catabolic spiral of CACS. There are not enough data to advise the use of parenteral nutritional support, hydrazine, cyproheptadine, tetrahydrocannabinol or nandrolone decanoate. Corticosteroids are useful in additional analgesia and fast palliation of very weak and debilitated patients in the final episode of their disease. Recent data in non-small cell lung cancer patients are in favour of the use of high-dose progestagens to improve both appetite and weight.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
J.F. Vansteenkiste and S.G. Stroobants
The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology
Eur. Respir. J., April 1, 2001; 17(4): 802 - 820.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. F. Vansteenkiste, S. G. Stroobants, P. J. Dupont, P. R. De Leyn, E. K. Verbeken, G. J. Deneffe, L. A. Mortelmans, and M. G. Demedts
Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose–Positron Emission Tomography Scan in Non–Small-Cell Lung Cancer: An Analysis of 125 Cases
J. Clin. Oncol., October 1, 1999; 17(10): 3201 - 3206.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. F. Vansteenkiste, P. R. De Leyn, G. J. Deneffe, G. Stalpaert, K. L. Nackaerts, T. E. Lerut, and M. G. Demedts
Survival and Prognostic Factors in Resected N2 Non-Small Cell Lung Cancer: A Study of 140 Cases
Ann. Thorac. Surg., May 1, 1997; 63(5): 1441 - 1450.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.